According to the company’s data, its sales revenues increased by 9.2% over the year – from 86.34 million lei in 2023 to 94.25 million lei in 2024. At the same time, the cost of sales rose by 12.3% – from 78.66 million lei to 88.32 million lei, while administrative expenses increased by 42.4% – from 10.79 million lei to 15.37 million lei.
The operating activity in 2024 resulted in losses of 6.53 million lei against a profit of 5.14 million lei a year earlier.
Sanfarm-Prim’s administration told Logos Press that the loss is partly explained by the participation in the “Farmacia in satul tau” program, which required investments. Thus, the company opened several pharmacies in rural areas, each of which was invested about 200-300 thousand lei. Secondly, Sanfarm-Prim invested part of its funds in the renovation of its premises and the purchase of equipment to meet the Good Distribution Practice standards. GDP is an international standard that targets logistics operators and distributors whose activities are related to medicines.
The company said that the company’s authorized capital at the end of 2024 amounted to 4.5 million lei. In 2025, it was decided to increase it by 50 per cent to 6.7 million lei by increasing the nominal value of shares from 10 to 15 lei per share.
Sanfarm-Prim remains a prominent domestic operator that deals with import, storage, wholesale and retail of pharmaceuticals, offering more than 2,000 drugs.
Approximately 99% of this company is owned by the state. Today Sanfarm-Prim is managed by the Public Property Agency.
